Skip to main content

Table 2 Proteolytic enzymes, CEA and CA 19-9 in correlation with Dukes classification.

From: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

Stage

CATB

CATL

uPA

PAI-1

CEA

CA 19-9

DUKES A (n = 7)

4.50

(2.4–37.3)

1.10

(1.0–35.3)

0.30

(0.2–0.62)

32.81

(17.2–66.7)

3.00

(0.6–3.4)

6.80

(3.0–11.5)

DUKES B (n = 12)

6.75

(3.2–23.8)

1.00

(1.0–12.3)

0.29

(0.1–0.79)

39.09

(13.5–108.1)

2.00

(0.6–21.1)

7.65

(1.0–35.0)

DUKES C (n = 23)

8.60

(3.6–35.7)

1.10

(1.0–34.1)

0.26

(0.1–0.79)

52.54

(13.8–126.4)

2.20

(0.4–235.0)

9.20

(1.0–78.6)

DUKES D (n = 14)

24.25*§

(9.2–39.3)

4.55

(1.0–35.2)

0.29

(0.12–0.42)

82.03**

(38.7–138.6)

8.30#

(1.9–74.6)

35.85**

(4.6–540.0)

Kruskall-Wallis analysis of variance (P value)

P = 0.0002

P = NS

P = NS

P = 0.01

P = 0.003

P = 0.001

  1. Cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 levels in association with Dukes classification of colorectal cancer expressed in ng/ml (median values and range)
  2. Statistics:
  3. *P < 0.01, Dukes D vs Dukes A and B
  4. §P < 0.05, Dukes D vs Dukes C
  5. **P < 0.05, Dukes D vs Dukes A, B and C
  6. #P < 0.01, Dukes D vs Dukes A, B and C
  7. Abbreviations: DUKES A: Dukes stage A; DUKES B: Dukes stage B; DUKES C: Dukes stage C; DUKES D: Dukes stage D; CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; NS: not significant